Severe Adverse Reaction to Vemurafenib in a Pregnant Woman with Metastatic Melanoma
Research output: Contribution to journal › Article › Academic › peer-review
Targeted therapies have drastically changed the management of metastatic melanoma and have shown encouraging results on tumour progression but are also known for their high rates of adverse reactions. In general, targeted therapies are contraindicated during pregnancy due to concerns about teratogenesis. For the BRAF V600 inhibitor vemurafenib, the available literature about the effects on human pregnancy is limited to a single case report. In patients with metastatic melanoma that wish to continue their pregnancy, targeted therapies like vemurafenib offer the only possibility of improving maternal outcome. In this article, we report on a pregnant woman with metastatic melanoma who was treated with vemurafenib during pregnancy and experienced a fatal adverse reaction.
de Haan, J., van Thienen, J. V., Casaer, M., Hannivoort, R. A., van Calsteren, K., van Tuyl, M., ... Painter, R. C. (2018). Severe Adverse Reaction to Vemurafenib in a Pregnant Woman with Metastatic Melanoma. Case Reports in Oncology, 11(1), 119-124. https://doi.org/10.1159/000487128